Stock Traders Purchase High Volume of Put Options on Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) saw some unusual options trading activity on Monday. Investors purchased 37,691 put options on the stock. This is an increase of approximately 38% compared to the average volume of 27,275 put options.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock opened at $22.21 on Tuesday. The firm has a fifty day moving average of $17.89 and a two-hundred day moving average of $17.56. The firm has a market cap of $25.16 billion, a P/E ratio of -26.13, a P/E/G ratio of 0.99 and a beta of 0.79. Teva Pharmaceutical Industries has a 1-year low of $10.34 and a 1-year high of $22.25. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Barclays raised their price target on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 18th. JPMorgan Chase & Co. lifted their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Finally, UBS Group boosted their target price on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $20.88.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the sale, the executive vice president now directly owns 44,104 shares in the company, valued at $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.55% of the company’s stock.

Institutional Trading of Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently bought and sold shares of the company. UMB Bank n.a. grew its position in shares of Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after acquiring an additional 2,067 shares in the last quarter. Smithfield Trust Co boosted its holdings in Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after purchasing an additional 980 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in Teva Pharmaceutical Industries during the third quarter valued at $50,000. Claro Advisors LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth $52,000. Finally, Mark Sheptoff Financial Planning LLC bought a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter worth about $57,000. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.